Total neoadjuvant therapy in rectal cancer: a review across studies

[1] Des Guetz G, Landre T, Bollet MA, Mathonnet M, Quéro L. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancers (Basel). 2021 Nov 30;13(23):6035. Des GuetzG LandreT BolletMA MathonnetM QuéroL Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis Cancers (Basel) 2021 Nov 30 13 23 6035 Search in Google Scholar

[2] Petrelli F, Coinu A, Lonati V, Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis. 2015 Apr;30(4):447–57. PetrelliF CoinuA LonatiV BarniS A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer Int J Colorectal Dis 2015 Apr 30 4 447 57 Search in Google Scholar

[3] Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Jul;16(7):874–901. BensonAB VenookAP Al-HawaryMM CederquistL ChenYJ CiomborKK Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2018 Jul 16 7 874 901 Search in Google Scholar

[4] Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021 Sep;18(9):547–57. ChaftJE RimnerA WederW AzzoliCG KrisMG CasconeT Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer Nat Rev Clin Oncol 2021 Sep 18 9 547 57 Search in Google Scholar

[5] Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther. 2020;14:2423–33. WangH MaoX Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer Drug Des Devel Ther 2020 14 2423 33 Search in Google Scholar

[6] Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016 Jun;21(6):708–15. YinM JoshiM MeijerRP GlantzM HolderS HarveyHA Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis Oncologist 2016 Jun 21 6 708 15 Search in Google Scholar

[7] Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018 Mar;51:120–7. CoccoliniF NardiM MontoriG CeresoliM CelottiA CascinuS Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials Int J Surg 2018 Mar 51 120 7 Search in Google Scholar

[8] Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29–42. BahadoerRR DijkstraEA van EttenB MarijnenCAM PutterH KranenbargEMK Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial Lancet Oncol 2021 Jan 22 1 29 42 Search in Google Scholar

[9] Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Dec;22(5):702–15. ConroyT BossetJF EtiennePL RioE FrançoisÉ Mesgouez-NeboutN Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 2021 Dec 22 5 702 15 Search in Google Scholar

[10] Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019 Aug 1;30(8):1298–303. CisełB PietrzakL MichalskiW WyrwiczL RutkowskiA KosakowskaE Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study Ann Oncol 2019 Aug 1 30 8 1298 303 Search in Google Scholar

[11] Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022 Dec 20;40(15):1681–92. JinJ TangY HuC JiangLM JiangJ LiN Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) J Clin Oncol 2022 Dec 20 40 15 1681 92 Search in Google Scholar

[12] Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022 Jan 1;8(1):e215445. FokasE Schlenska-LangeA PolatB KlautkeG GrabenbauerGG FietkauR Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial JAMA Oncol 2022 Jan 1 8 1 e215445 Search in Google Scholar

[13] Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 Aug 10;40(23):2546–56. Garcia-AguilarJ PatilS GollubMJ KimJK YuvalJB ThompsonHM Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy J Clin Oncol 2022 Aug 10 40 23 2546 56 Search in Google Scholar

[14] Conroy T, Etienne PL, Rio E, Evesque L, Mesgouez-Nebout N, Vendrely V, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. JCO. 2023 Jun 10;41(17_suppl):LBA3504–LBA3504. ConroyT EtiennePL RioE EvesqueL Mesgouez-NeboutN VendrelyV Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial JCO 2023 Jun 10 41 17_suppl LBA3504 LBA3504 Search in Google Scholar

[15] Bujko K, on behalf of the Polish Colorectal Study Group. Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: Results of a Polish II multicentre phase III study. JCO. 2016 Feb 1;34(4_suppl):489–489. BujkoK on behalf of the Polish Colorectal Study Group Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: Results of a Polish II multicentre phase III study JCO 2016 Feb 1 34 4_suppl 489 489 Search in Google Scholar

[16] Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). JCO. 2023 Jun 10;41(17_suppl):LBA2–LBA2. SchragD ShiQ WeiserMR GollubMJ SaltzLB MusherBL PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048) JCO 2023 Jun 10 41 17_suppl LBA2 LBA2 Search in Google Scholar

[17] Pei-Rong Ding, Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial, LBA26, ESMO 2023 DingPei-Rong Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial, LBA26 ESMO 2023 Search in Google Scholar

[18] ASCO, Cancer.net, https://www.cancer.net/cancer-types/colorectal-cancer/risk-factors-and-prevention ASCO Cancer.net https://www.cancer.net/cancer-types/colorectal-cancer/risk-factors-and-prevention Search in Google Scholar

[19] Donnelly M, Ryan OK, Ryan ÉJ, Creavin B, O’Reilly M, McDermott R, et al. Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials. Br J Surg. 2023 Sep 6;110(10):1316–30. DonnellyM RyanOK RyanÉJ CreavinB O’ReillyM McDermottR Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials Br J Surg 2023 Sep 6 110 10 1316 30 Search in Google Scholar

[20] Li XT, Zhang XY, Sun YS, Tang L, Cao K. Evaluating rectal tumor staging with magnetic resonance imaging, computed tomography, and endoluminal ultrasound: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(44):e5333. LiXT ZhangXY SunYS TangL CaoK Evaluating rectal tumor staging with magnetic resonance imaging, computed tomography, and endoluminal ultrasound: A meta-analysis Medicine (Baltimore) 2016 Nov 95 44 e5333 Search in Google Scholar

[21] Crimì F, Lacognata C, Cecchin D, Zucchetta P, Pomerri F. Rectal cancer staging: An up-to-date pictorial review. J Med Imaging Radiat Oncol. 2018 Jul 5; CrimìF LacognataC CecchinD ZucchettaP PomerriF Rectal cancer staging: An up-to-date pictorial review J Med Imaging Radiat Oncol 2018 Jul 5 Search in Google Scholar

[22] Fokas E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, Buyse M, Rödel C, Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020:e252–e264 FokasE SmithJJ Garcia-AguilarJ Glynne-JonesR BuyseM RödelC Outcome measures in multimodal rectal cancer trials Lancet Oncol 2020 e252 e264 Search in Google Scholar

[23] Johnson GGRJ, Park J, Helewa RM, Goldenberg BA, Nashed M, Hyun E. Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can J Surg. 2023;66(2):E196–201. JohnsonGGRJ ParkJ HelewaRM GoldenbergBA NashedM HyunE Total neoadjuvant therapy for rectal cancer: a guide for surgeons Can J Surg 2023 66 2 E196 201 Search in Google Scholar

[24] Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022 Jun 23;386(25):2363–76. CercekA LumishM SinopoliJ WeissJ ShiaJ Lamendola-EsselM PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer N Engl J Med 2022 Jun 23 386 25 2363 76 Search in Google Scholar

[25] Zhenyu Lin, Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION), LBA25, ESMO 2023. LinZhenyu Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION), LBA25 ESMO 2023 Search in Google Scholar